UNSPSC 51171725: Loperamide oxide monohydrate

This classification denotes an opioid and antidiarrheal agent with the molecular formula C29H33ClN2O3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H3VOT77DE1, chemically known as 1-piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-n,n-dimethyl-alpha,alpha-diphenyl-, 1-oxide, (e)- but more generally known as loperamide oxide, which bears US NIH Compound Identifier 71421. European Medicines Agency schedules Loperamide oxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08573MIG.

UNSPSC 51171725 Loperamide oxide monohydrate is a Commodity code used to classify a specific pharmaceutical active ingredient, but the recent state and local contract opportunities tagged under this code do not reflect procurement of loperamide oxide monohydrate itself. Instead, the tagged opportunities span offender drug testing services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution — none of which involve this particular compound. The code shows a mismatch between its nominal scope and the work actually being solicited under it in the state and local market. State and local governments tagging procurement activity to this code are pursuing broader pharmaceutical sourcing and testing services rather than procurement of the specific active ingredient named in the code taxonomy.

The geographic spread of recent activity includes Texas (Collin County Community Supervision and Corrections Department, Texas Health and Human Services Commission) and Minnesota (Minnesota Multistate Cooperative Purchasing Alliance). The most concrete recent opportunity is Collin County's RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, seeking immunoassay screening and LC/MS/MS or GC/MS confirmation across two collection sites in Plano and McKinney with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026. The Minnesota MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, establishes multiple contracts distributed across state and local government facilities, with contract terms effective July 1, 2026. A Texas HHS RFI (HHS0017013) released in March 2026 sought market intelligence on direct-to-manufacturer prescription programs but carried no formal award value or budget commitment. The code shows limited decision-relevance to firms seeking work under its nominal pharmaceutical-ingredient classification.